Beyond weight, the SELECT trial (N=17,604) published in the New England Journal of Medicine in 2023 showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease, over a median follow-up of 39.8 months (HR 0.80 to 95% CI 0.72 to 0.90)
Wegovy (Semaglutide Injection) Wegovy is the semaglutide solution for weight management, offering once-a-week injections
The native or two modified GLP-1 (mGLP-1) with Ala8Gly substitution or Ala8Gly, Lys26Gln, and Lys34Asp substitutions were genetically fused to the N-terminus of HSA-binding DARPin through a rigid helical linker (EAAAK) 3 to create the fusion proteins, denoted as nGLP1-DARPin, mGLP1-DARPin-1, and mGLP1-DARPin-2, respectively
Their findings match existing clinical data, supporting the notion that probiotics can influence the MGBA, perhaps as a complementary method of intervention against the advancing PD phenotypes